The
kinase activity of this protein is essential for its role in cell signaling pathways.
这个蛋白质的激酶活性对其在细胞信号传导途径中的作用至关重要。
The
kinase inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia.
伊马替尼（imatinib）作为激酶抑制剂，已彻底改变了慢性髓系白血病的治疗。
Activation of the PI3K/Akt
kinase cascade leads to cell survival and proliferation.
PI3K/Akt激酶通路的激活导致细胞存活和增殖。
Cyclin-dependent
kinases play a crucial role in regulating the cell cycle.
周期蛋白依赖性激酶在调控细胞周期中起着关键作用。
The Akt/mTOR pathway is a well-known target for cancer therapeutic
kinase inhibitors.
Akt/mTOR途径是抗癌药物激酶抑制剂的常用靶点。
Epidermal growth factor receptor (EGFR)
kinase inhibitors have shown promise in treating lung cancer.
表皮生长因子受体（EGFR）激酶抑制剂在肺癌治疗中展现出前景。
Kinase phosphorylation events often serve as molecular switches in cellular processes.
激酶磷酸化事件常常作为细胞过程中的分子开关。
The Src family
kinases are involved in various cellular processes, including cell adhesion and migration.
Src家族激酶参与多种细胞过程，如细胞粘附和迁移。
Dysregulation of the Ras/Raf/MEK/ERK
kinase cascade can lead to cancer development.
Ras/Raf/MEK/ERK激酶级联调节失常可能导致癌症发生。
Researchers are constantly exploring new
kinase targets to develop more effective therapies for neurological disorders.
研究人员正在不断寻找新的激酶靶点，以开发更有效的神经系统疾病疗法。
Pfizer, the global biopharmaceutical company, held a launch ceremony for Cibinqo – an oral, once-daily highly selective JAK1 (Janus kinase 1) inhibitor, for treating adult patients with moderate-to-severe atopic dermatitis -- in China on Sunday.
周日，全球生物制药公司辉瑞在中国举行了Cibinqo的上市仪式。Cibinqo是一种口服的、每天一次的高选择性JAK1（Janus激酶1）抑制剂，用于治疗中重度特应性皮炎的成年患者。
Biopharmaceutical companyxa0Pfizer announced on Friday that Lorbrena, the world's first third-generation anaplastic lymphoma kinase inhibitor, has been approved by China's National Medical Products Administration for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.
生物制药公司xa0Pfizer周五宣布，世界上第一种第三代间变性淋巴瘤激酶抑制剂Lorbrena已被中国国家药品监督管理局批准用于治疗ALK阳性的局部晚期或转移性癌症患者。
The tablet is a new anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor used to treat those suffering from non-small cell lung cancer.
该片是一种新型间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂，用于治疗癌症患者。
The drug belongs to a class of pharmaceuticals called Bruton's tyrosine kinase (BTK) inhibitors, which inhibit the enzyme BTK and its downstream signaling to result in growth inhibition and death of certain tumorous cells.
这种药物属于一类名为布鲁顿酪氨酸激酶（BTK）抑制剂的药物，它们通过抑制BTK酶及其下游信号传导，从而导致某些肿瘤细胞的生长抑制和死亡。
未经许可，严禁转发。QQ交流群：688169419